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Background. The expression of MHC class I genes is repressed in mature neurons. The molecular basis of this regulation is
poorly understood, but the genes are particularly rich in CpG islands. MeCP2 is a transcriptional repressor that binds to
methylated CpG dinucleotides; mutations in this protein also cause the neurodevelopmental disease called Rett syndrome.
Because MHC class I molecules play a role in neuronal connectivity, we hypothesised that MeCP2 might repress MHC class I
expression in the CNS and that this might play a role in the pathology of Rett syndrome. Methodology. We show here that
transiently transfected cells expressing high levels of MeCP2 specifically downregulate cell-surface expression of MHC class I
molecules in the neuronal cell line N2A and they prevent the induction of MHC class I expression in response to interferon in
these cells, supporting our first hypothesis. Surprisingly, however, overexpression of the mutated forms of MeCP2 that cause
Rett syndrome had a similar effect on MHC class I expression as the wild-type protein. Immunohistological analyses of brain
slices from MECP2 knockout mice (the MeCP2
tm1.1Bird strain) demonstrated a small but reproducible increase in MHC class I
when compared to their wild type littermates, but we found no difference in MHC class I expression in primary cultures of
mixed glial cells (mainly neurons and astrocytes) from the knockout and wild-type mice. Conclusion. These data suggest that
high levels of MeCP2, such as those found in mature neurons, may contribute to the repression of MHC expression, but we find
no evidence that MeCP2 regulation of MHC class I is important for the pathogenesis of Rett syndrome.
Citation: Miralve `s J, Magdeleine E, Kaddoum L, Brun H, Peries S, et al (2007) High Levels of MeCP2 Depress MHC Class I Expression in Neuronal
Cells. PLoS ONE 2(12): e1354. doi:10.1371/journal.pone.0001354
INTRODUCTION
Mutations in the X-linked gene MECP2 cause Rett syndrome
(RTT) [1–3], a progressive neurodevelopmental disorder that
affects around 1 in 10,000 female births [4]. Girls with RTT
develop normally until 6–18 months old, when they begin to
regress, losing the speech and hand skills they had acquired. Most
patients develop severe mental retardation, seizures, repetitive
hand movements, irregular breathing and motor-control problems
[5–7]. MECP2 encodes the methyl-CpG-binding protein 2
(MeCP2) [8,9], which is thought to regulate gene expression, but
we do not yet understand how mutations in this protein produce
the pathological features of RTT.
MECP2 knockout mice [10–12] and mice expressing a
truncated form of MeCP2 [13] display a RTT-like phenotype,
demonstrating that MeCP2 deficiency is sufficient to induce the
syndrome. Moreover, mice in which MECP2 was conditionally
deleted in neurons had a similar phenotype to RTT patients
[10,14], and MeCP2-deficient mice were cured by expression of a
transgenic MECP2 gene specifically in post-mitotic neurons [15].
These findings indicate that the pathology of RTT is due to the
lack of MeCP2 in the mature central nervous system (CNS). Two
recent studies have shown that the neurological defects in mutant
mice are reversed by restoration of MeCP2 expression in neurons,
even at late postnatal stages [16,17], suggesting that gene therapy
may be feasible.
The MECP2 mRNA is alternatively spliced to generate two
protein isoforms (MeCP2A and MeCP2B) that differ at their N-
termini. Both forms are expressed ubiquitously, but MeCP2B is
more abundant than MeCP2A in the CNS [18,19]. MeCP2
represses transcription [20] by binding through its methyl-CpG-
binding domain (MBD) [21] to methylated CpG nucleotides
[22,23] and recruiting co-repressors that bind to its transcription
repression domain (TRD) [24–27]. Other studies, however,
indicate that MeCP2 is a multifunctional protein that affects gene
regulation at many levels: MeCP2 interacts with an RNA-binding
protein called Y box-binding protein 1 to regulate splicing of target
RNAs [28,29]; two studies suggest that MeCP2 influences gene
expression by participating in chromatin architecture, indepen-
dently of its capacity to bind methylated DNA [30,31]; moreover,
MeCP2 associates with the DNA methyltransferase Dnmt1 bound
to hemi-methylated DNA and may thus participate in maintaining
the methylation state of newly synthesised DNA [32,33].
Our knowledge of the activities of MeCP2 suggests that the
pathologies associated with MECP2 mutations are most likely due
to the misregulation of neuronal genes. Several studies have
identified possible target genes that are controlled by MeCP2,
including the gene encoding brain-derived neurotrophic factor
(BDNF) [34–36], genes encoding inhibitors of differentiation [37],
and genes regulated by glucocorticoids [38]; their expression is
altered in MECP2 knockout mice, but whether this is responsible
for the neuropathology seen in RTT remains questionable.
We hypothesised that genes encoding MHC class I molecules
(MHC class I) might be amongst those that MeCP2 regulates in
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[39]. Two studies have demonstrated that expression of MHC
class I is dynamically regulated during the post-natal development
of the CNS and that MHC class I expression is necessary for the
activity-dependent synaptic rearrangements that occur during
normal brain development and for normal synaptic plasticity in
the mature hippocampus [40,41]. If MHC class I expression was
regulated by MeCP2, defects in these developmental functions of
MHC class I might contribute to the symptoms of RTT.
MHC class I is generally not expressed in adult brain except in
response to cytokines (i.e. inflammation) or injury [42]. This is
believed to protect nervous tissue, which regenerates poorly, from
cytotoxic attack by the immune system. Several lines of evidence,
however, suggest that MHC class I is expressed in specific areas of
the mature brain, as well as during brain development, and they
evoke a function for MHC class I molecules in neuronal signalling
[41,43–46]. This suggests that, rather than being simply shut
down, MHC class I genes must be very finely regulated
throughout the CNS by activators and inhibitors that, on the
one hand, allow their function during development and, on the
other hand, ensure their silencing in the majority of neurons in
which their expression could be detrimental.
We reasoned that misregulated expression of MHC class I in the
brain due to mutations in MeCP2 might disturb the establishment
and maintenance of neuronal connections and remodelling in the
hippocampus during early child development and thus account for
the neurodevelopmental disorders of RTT. We therefore investi-
gated whether MHC class I gene expression is under the control of
MeCP2 in neuronal cell lines in culture and whether MHC class I
gene expression is affected in MECP2 knockout mice.
RESULTS
Overexpression of MeCP2 downregulates basal MHC
class I
To investigate whether MeCP2 represses MHC class I expression,
we transfected the murine neuronal cell line N2A with pCMX
plasmids that transiently express either human or murine MeCP2A.
Forty-eight hours after transfection, we evaluated by flow cytometry
the cell surface levels of K
k,L
d and D
d (the three ‘classical’ MHC
class I molecule heavy chains expressed by N2A), b-2-microglobulin
(the light chain subunit of MHC class I) and, as control, the
transferrin receptor, a cell surface glycoprotein of similar size and
half-life to MHC molecules (Figure 1). The expression of MeCP2 in
transfected cells was detected by a rabbit anti-MeCP2 polyclonal
antibodyon cells fixed andpermeabilised after they hadbeenstained
for MHC class I cell surface expression. Dot plot representative
examples of these analyses are shown on Figure 1A, where each dot
represents an individual cell, and an decrease in MHC staining
results in a shift to the left, and an increase in MeCP2 in an upward
shift. Because these are transient transfections, MeCP2 overexpres-
sionisdetectedinonlya certain percentage(typically20–30%)of the
cells. As can be seen for all MHC class I molecules ( K
k,L
d,D
d )a n d
b-2-microglobulin, in the cloud of cells overexpressing MeCP2, we
detected a clear shift to the left compared to the lower cloud of
untransfected cells and to mock-transfected cells, indicating a
reduction of the cell surface expression of all these molecules in
the cells that overexpress MeCP2. This effect appears to be specific
for these molecules since the level of transferrin receptor was
basically unaffected by MeCP2 overexpression. The reproducibility
and statistical significance of these observations was ascertained by
repeating this experiment many times, which also allowed us to
conclude that MeCP2 overexpression results in a similar 40%
decrease of all three MHC class I molecules and of b-2-
microglobulin (Figure 1B). In the experiment shown, the mock-
transfected cells were simply treated with the transfection reagent,
but similar results wereobtained when the negative control consisted
of empty plasmids, or plasmids expressing other proteins such as
GFP (not shown).
No functional difference has been described between the two
isoforms of MeCP2, MeCP2A and MeCP2B. We therefore
explored whether these two isoforms had the same effect on
MHC class I molecules and whether their effects might differ
according to the cell type in which they are expressed. We
transfected vectors encoding the Myc-tagged version of human
MeCP2A or MeCP2B into either N2A or the mouse fibroblast cell
line NIH 3T3. In this experiment, we detected MeCP2 expression
by using an anti-Myc9E10 monoclonal antibody because it
produced a much stronger signal than the anti-MeCP2 antibody.
The level of MHC class I was evaluated at the same time by using a
rat anti-pan-MHC antibody, M1/42. The double staining in mock-
transfected and transfected cells was analysed by flow cytometry.
MeCP2 overexpression induced a similar extent of repression of
MHC class I irrespective of the isoform or cell type in which it was
expressed (Figure 1C):the cellsurfacelevelofMHCclassIdecreased
by approximately 35% when compared to the basal level (p,0.01 in
N2A;p,0.001 inNIH 3T3)wheneitherMeCP2AorMeCP2Bwere
overexpressed in N2A or in NIH 3T3 cells.
We noted a correlation in these experiments between the
repressive effect exerted by MeCP2 on MHC class I and b-2-
microglobulin and the quantity of MeCP2 expressed by the
transfected cells: cells expressing high levels of MeCP2 (dotted
circle, Figure 1D) had less MHC class I on their surface than cells
expressing MeCP2 at lower levels (continuous circle), which
expressed levels of MHC class I similar to those in cells in which
no MeCP2 staining was detected and to those in mock-transfected
cells. Repression of MHC class I expression by MeCP2 therefore
appears to require very high levels of MeCP2. We generated stably
transfected lines of N2A expressing either MeCP2A or MeCP2B
but the levels of protein expressed by these cells was relatively low
(at best comparable to those in the continuous circle in Figure 1D).
It is therefore of little surprise that the levels of MHC class I
expressed by those cells was not discernibly different from that of
untransfected cells (not shown). Evaluation by quantitative western
blot of the levels of MeCP2 protein expressed in these various
transfected cells revealed bands of comparable intensities in stable
transfectants and in brain extracts, and bands that were two to five
fold more intense in transiently transfected populations (not
shown). Since mature neurons represent approximately 15% of all
cells in the brain parenchyma, we can further estimate that our
stable transfectants express levels of MeCP2 which are roughly one
sixth of those found in mature neurons. Conversely, since the
efficiency of the transient transfections in this experiment was
approximately 10%, we estimate that the levels of MeCP2 attained
in high expressors after transient transfections are 20 to 50 fold
higher than the levels in stable transfectants (and therefore three to
eight fold higher than in intra-cerebral neurons).
Overexpression of MeCP2 markedly reduces MHC
class I upregulation by IFN-c
The cytokine IFN-c transactivates MHC class I expression
predominantly by binding to IFN regulatory factor-1, which
binds, in turn, to the interferon-stimulated response element,
ISRE, a GC-rich region and therefore a potential binding site also
for MeCP2 [47]. Since MeCP2 appeared to act as a repressor of
MHC class I expression (Figure 1), we wanted to test whether it
would interfere with transactivation of MHC class I expression by
MeCP2 Reduces MHC I Expression
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driving the expression of either murine or human forms of
MeCP2A. The following day, these transiently transfected cells
were divided into two flasks that were either treated or not with
IFN-c for 48 hrs. The levels of cell-surface MHC class I, b-2-
microglobulin and transferrin receptor, and intracellular MeCP2,
were evaluated by flow cytometry as in the previous experiments
(Figure 2). As can be seen by the shift of the clouds between the
higher and the lower panels, treatment with IFN-c resulted in a
two- to four-fold induction of MHC class I and b2-microglobulin
in both mock-transfected populations and transfected populations
(Figure 2A). Individual transfected cells expressing MeCP2 at high
levels, however, had little more L
d and b2-microglobulin when
treated with IFN-c than untreated MeCP2-expressing cells
(compare the populations encircled in Figure 2A IFN-c with those
without IFN-c). Cells overexpressing MeCP2 therefore appear to
respond to IFN-c by upregulating MHC class I to a much lesser
extent than do cells not expressing MeCP2.
The statistical significance of the differences in response to IFN-
c was confirmed for all three MHC class I molecules expressed by
Figure 1. MeCP2 overexpression diminishes MHC class I expression. N2A cells transfected with pCMX vectors expressing either murine or human
MeCP2 were immunostained for one of the three MHC class I molecules (K
k,L
d or D
d), b2-microglobulin or the transferrin receptor on the cell surface
as well as for intracellular MeCP2. The level of staining was then analysed by fluorescence-activated cell sorting. Panel A: Dot plots of the amount of
surface antigen (x-axis) against the amount of intracellular MeCP2 (y-axis) in cells transiently transfected with pCMX expressing human MeCP2 and
analysed 48 hrs later. Panel B: For each kind of staining, the variation in expression level was calculated as the ratio of MFI of MeCP2 overexpressing
cells over MFI of mock-transfected cells. The histograms summarise the mean (6SEM) of the variation in cell surface levels from 15 independent
transfections with vectors expressing mouse MeCP2A (grey fill) and 12 independent transfections with vectors expressing human MeCP2A (black fill).
Panel C: N2A and NIH3T3 cells were transfected with empty pcDNA3.1(+) (mock cells) or expressing Myc-tagged human MeCP2A or B isoforms. 48 h
after transfection, cells were subjected to double staining against cell surface MHC class I molecules and intracellular Myc-tagged MeCP2, then
analyzed by flow cytometry. The variation in expression level of MHC class I molecules was calculated as the ratio of MFI of MeCP2 over-expressing
cells over the MFI of mock cells. The histograms represent the mean (6SEM) of the cell surface level variation from 4 independent transfections with
each of the vectors. Panel D: A representative example of dot-plots obtained for double immunostaining of transiently transfected N2A cells with
anti-Myc 9E10 and rat-anti-mouse-MHC I M1/42 monoclonal antibodies. Dotted and continuous circles indicate the different populations expressing
high and intermediate levels of MeCP2, respectively. Statistical significance of difference between groups was analysed by using an unpaired t-test
(**, p,0.01 ; ***, p,0.001).
doi:10.1371/journal.pone.0001354.g001
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k,L
d,D
d ) and for b-2-microglobulin in six
independent experiments (Figure 2B), whereas the levels of
transferrin receptor were not significantly affected. This effect
was also observed in other cell lines such as NIH 3T3 fibroblasts
and human HEK 293 cells (not shown).
MeCP2 mutants retain their repressive effect on
MHC class I expression
Many disease-causing mutations of MECP2 have been described
[48]. Among them, some occur more frequently than others, and/
or have been more thoroughly characterised. To investigate the
effect of these MECP2 mutations on MHC class I expression, we
transiently transfected the N2A cell line with plasmids expressing
well-characterised mutants of both the A and B isoforms of MeCP2
(T158M, R133C, R306C and R308*). The point mutations
T158M, R133C and R306C are located in the functional MBD
and TRD domains of the protein (Figure 3A). The mutant form
that is truncated after the R308 residue corresponds to the form of
MeCP2 found in the mouse model of RTT generated by Dr.
Zoghbi’s group [13]. We performed mutagenesis on vectors
expressing either the A or B form of Myc-tagged MeCP2. All the
mutated plasmids were sequenced and checked for functional
expression and intracellular localisation of the wild-type and
mutated MeCP2 proteins by anti-Myc immunofluorescence on
transiently transfected N2A cells (Figure 3B). All the mutant forms
of Myc-taged MeCP2 were located in intranuclear punctate
structures typical of the wild-type protein, which forms foci on
heterochromatin [22,49] (data is shown for the R133C MeCP2A-
Myc mutant and the wild-type pMeCP2A-Myc protein only).
Subsequently, we evaluated the cell-surface expression level of
MHC class I in the transiently transfected N2A cells by flow
cytometry using the rat anti-pan-MHC I antibody M1/42, as
before. The intracellular MeCP2 level was evaluated based on the
intensity of immunostaining for the Myc tag, and was found to be
similar to the wild-type for both the A and B forms of the four
mutants. The R133C MeCP2A-Myc mutant had the same effect as
its wild-type counterpart on the cell-surface level of MHC class I
(Figure 3C), whereas neither mutant nor wild type had a significant
effect on expression of the transferrin receptor (not shown). Similar
Figure 2. Transient overexpression of MeCP2 inhibits MHC class I induction by IFN-c. N2A cells transfected with pCMX vectors expressing murine
or human MeCP2 were treated or not with IFN-c for 48 hrs and then double immunostained for cell surface b2-microglobulin, transferrin receptor or
MHC class I and intracellular MeCP2. Panel A: Dot-plots of transfected cells analysed by flow cytometry showing the cell surface level of the MHC class
I molecule L
d or b2-microglobulin (x-axis) plotted against the level of intracellular MeCP2 (y-axis). Panel B: The induction factor was calculated as the
ratio of MFI of treated cells (over-expressing MeCP2 or untransfected cells) on MFI of untreated N2A cells. Values used for the histogram are the mean
(6SEM) of induction factors obtained in seven independent transfection experiments. Statistical significance of difference between groups was
analysed by using an unpaired t-test (*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0001354.g002
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tested (Data for T158M R306C and R308* are not shown). Thus,
these mutations responsible for RTT do not abolish the repressive
effect of MeCP2 on MHC class I in cells in culture. These results
strongly suggest that the repressive function of MeCP2 on the levels
of MHC molecules expressed by transiently transfected cells in
vitro is unlikely to be directly related to the pathogenesis of Rett
syndrome.
Expression of MHC class I in cells from MeCP2-
knockout mice is no different to that in cells from
wild-type mice
Our data from experiments with cells in culture (above) suggest
that the genes encoding MHC class I and b2-microglobulin are
controlled by MeCP2; overexpression of normal MeCP2 down-
regulates their expression. To find out whether this is the case in
vivo, we investigated whether neuronal cells from MeCP2
knockout mice (MeCP2
tm1.1Bird) contained elevated levels of
MHC class I by performing immunohistochemistry on frozen
brain sections of MECP2 knockout hemizygous male (-/y) mice
and of their wild-type littermates using two different rat mono-
clonal antibodies directed against mouse MHC class I molecules.
The results we obtained suggest that there are slightly higher levels
of MHC class I expression in some regions of the brains of MeCP2
knockout mice than in the same regions of the wild-type control
brains (Figure 4). Although these differences were not always seen
for all brain areas of MECP2 knockout mice compared to their
control littermates, when a difference was seen, it was always for
higher expression in MECP2 knockout animals.
The immunohistochemistry approach did not allow us to
quantify the small variations we observed in MHC class I
expression between MeCP2 knockout and wild-type mice or to
identify the cell types that expressed MHC class I in the absence of
MeCP2 (neurons, astrocytes, oligodendrocytes or endothelial cells).
We therefore decided to look at primary cultures of brain cells
Figure 3. Mutant forms of MeCP2 that cause RTT retain their repressive effect on MHC class I expression. Panel A: Schematic representation of the
MeCP2 protein. Red and orange arrows indicate the positions of the mutations introduced in MeCP2 by site-directed mutagenesis (MBD: methyl-CpG
binding domain, TRD: transcription repression domain, WW: group II WW-domain-binding region). Panel B: N2A cells transfected with empty
pcDNA3.1 (mock cells), with pcDNA3.1 expressing Myc-tagged MeCP2A (pMeCP2A-myc) or with pcDNA3.1 expressing Myc-tagged MeCP2A with the
R133C point mutation (pMeCP2A-R133C-myc) were stained with mouse anti-Myc 9E10 monoclonal antibody, and FITC-labelled anti-mouse IgG
antibody. Coverslips were mounted in DAPI-containing ProLong Gold antifade reagent (Molecular Probes) before observation by fluorescence
microscopy. Panel C: N2A cells transfected as in panel B were double immunostained for cell surface MHC class I and intracellular Myc-tagged MeCP2,
then analysed by flow cytometry. Similar data were obtained for all four mutated forms of MeCP2A and MeCP2B (not shown), and these observations
were reproduced in three independent transfection experiments.
doi:10.1371/journal.pone.0001354.g003
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from individual 2-day-old mice born from crossing a heterozygous
female (MeCP2
tm1.1Bird +/2) with a wild-type male. The tail DNA
from each newborn mouse used to prepare the cell lines was
analysed to establish the genotype of each culture. On the second
day of culture, the MGCs were treated with IFN-c or not and then
analysed two days later for expression of MHC class I on the cell
surface by flow cytometry (Figure 5). The fibroblast cultures,
which took a few more days to establish, were similarly treated
with IFN-c after five days and analysed on the seventh day.
Figure 5A shows typical examples of histograms obtained with
wild-type and MeCP2
tm1.1Bird 2/y male littermates. Similar data
were obtained for all four genotypes: wild-type female (+/+) and
male (+/y), heterozygous mutant female (MeCP2
tm1.1Bird 2/+) and
hemizygous mutant male (MeCP2
tm1.1Bird 2/y).
Neurons, which we identified by their expression of bIII-tubulin
and their smaller size (see population R2, inset Figure 5A), had no
detectable MHC class I (grey-filled curves) when compared to
background (white-filled curves), and treatment with IFN-c
induced a small amount of MHC class I in cells from both the
wild-type and knockout animals. Astrocytes, which comprise the
majority of the population of large cells [50] (population R1, inset
Figure 5A), spontaneously expressed more MHC class I, which
was highly induced by IFN-c but no significant differences were
seen between the two genotypes. Although the populations in the
cultures of spleen-derived fibroblasts were much more heteroge-
neous, similar levels of MHC class I were found in the cells from
the wild-type and knockout animals. These measurements were
performed on cell cultures derived from 24 newborn animals from
nine independent litters, with very similar results.
To compare data obtained in independent experiments, we
plotted the fold-induction of MHC class I expression after
treatment with IFN-c compared to untreated cells. Figure 5B
displays the fold-induction of MHC class I by IFN-c in each cell
culture derived from an individual mouse as well as the mean for
cell cultures of each genotype. No significant differences were
found between wild-type and MeCP2-knockout cells. The defici-
ency in MeCP2 thus affects neither the basal nor the inducible
MHC class I expression level in primary MGC cultures.
DISCUSSION
Reports by Shatz and colleagues [40,41,51] have demonstrated
clearly that tight regulation of MHC class I genes in the CNS
contributes to the establishment and maintenance of neuronal
connections during development, as well as to plastic remodelling in
the hippocampus and to neuronal signalling in specific areas of the
brain [40,41,51]. We reasoned that the transcriptional repressor
MeCP2 might be involved in regulating MHC class I expression in
the CNS for three main reasons. Firstly, expression of MeCP2 is
strictly regulated during development [52–54] and specifically in
various cell types [55] and is highest in mature neurons [56,57],
which do not express MHC class I. Secondly, MeCP2 binds to
methylated cytidine residues on CpG dinucleotides [21] and the
genes for MHC class I are particularly rich in C/G residues [39].
Thirdly, mutations in the MECP2 gene are responsible for the
neurodevelopmental disorder RTT. We hypothesised that MeCP2
represses expression of MHC class I and that mutations responsible
for RTT might cause the loss of this activity.
In support of the first part of this hypothesis, we showed clearly
that overexpression of either of the two isoforms of MeCP2 by
transient transfection of neuronal and fibroblastic cell lines results
in reduced levels of MHC class I and b2-microglobulin at the cell
surface. Furthermore, overexpression of MeCP2 blocked induc-
tion of MHC class I in these cells in response to IFN-c. We could
not determine whether this decreased expression of MHC class I
and b2-microglobulin in response to MeCP2 overexpression was
due to reduced transcription, translation or transport to the cell
surface because the cells were transiently transfected; only cells
that expressed high levels of MeCP2 showed reduced levels of
MHC class I on their surface, so we could not quantify the levels of
mRNA by RT-PCR or northern blot.
The fact that we observed very similar extents of repression of
all three MHC class I forms (K
k,L
d and D
d) as well as of b2-
microglobulin suggests that MeCP2 probably does not act directly
on the promoters of the various loci encoding MHC class I, which
are not identical. These considerations lead us to think that the
effect of MeCP2 may be a more ‘global’, indirect mechanism than
transcriptional repression by binding to methyl cytosine in the
promoters.
Figure 4. Evaluation of MHC class I expression in adult mouse brain slices. Serial frozen sections of adult male wild-type and MeCP2
2/y littermates
were analysed for expression of MHC class I by immunohistochemistry using the rat R1-21.2 monoclonal antibody and EnVision detection technology
(Dako). For the negative control, the same staining process was used omitting the primary antibody. Similar results were obtained with the M1/42
monoclonal antibody. Similar results were obtained in independent experiments on brains from three different pairs of mice.
doi:10.1371/journal.pone.0001354.g004
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expressing cells might be due to an effect on chromatin
architecture encompassing the whole MHC region, which
includes, in addition to the MHC class I loci, other genes involved
in the assembly and transport of MHC molecules [58,59] that
might contribute to a global effect. If MeCP2 condenses the
chromatin in the MHC region, this might block access of
transcription factors and regulatory factors to the genes, as
suggested by the work of Georgel and colleagues [30]. Such
chromatin condensation would also explain the failure of IFN-c to
induce MHC class I in cells overexpressing MeCP2 if it prevented
IFN regulatory factors from binding to their response element.
Our findings that the MeCP2 forms mutated either in the MBD
or TRD domains conserve their repressive effect on MHC class I
expression strengthen this interpretation that MeCP2 has an
indirect effect on transcription through its effect on chromatin
architecture. These mutations affect only transcriptional repres-
sion by MeCP2, preventing it from binding to methylated DNA
Figure 5. Deletion of MECP2 does not affect basal or IFN-c -induced MHC class I expression in primary cultures of mixed glial cells. Mixed glial
cell cultures established from two-day old wild-type, MeCP2
+/2 and MeCP2
2/y mice (10, 6 and 8 animals per group, respectively) were treated or not
with IFN-c on the second day of culture and analysed two days later by flow cytometry for MHC class I expression. Neurons were identified by their
intracellular staining with an anti-b-III-tubulin antibody (inset). Large cells, containing mainly astrocytes, were analysed separately by an appropriate
forward/side scatter gate. Primary spleen fibroblasts from the same mice were also subjected or not to IFN-c treatment and stained for their MHC
class I expression. Panel A: Representative histograms showing cell surface staining (x axis) against cell number (y axis), obtained with cells from wild-
type and MeCP2
2/y male littermates. White-filled curves represent background staining, gray-filled curves represent MHC I-specific staining. Panel B:
MHC class I fold-induction in response to IFN-c was calculated as the ratio of MFI of treated cells (induced MHC I level) on MFI of untreated cells (basal
MHC I level). Grey-filled squares show MHC class I fold-induction for individual mice and for each cell type. White-filled squares represent the group’s
mean of fold-inductions (6SD).
doi:10.1371/journal.pone.0001354.g005
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the protein are not affected, particularly its capacity to silence gene
expression by driving chromatin condensation [30,60] and
stabilising large silencing chromatin loops [31]. The ability of
MeCP2 to condense chromatin by methylation-independent DNA
binding relies on regions within the N-terminal 294 residues,
distinct from the MBD [30,61].
MeCP2 induces chromatin condensation in three successive
steps: first, it binds to the linker DNA between nucleosomes;
second, it brings the nucleosomes together in a ‘stem conforma-
tion’ through DNA–protein interactions, and third, it binds to the
nucleosomes themselves to produce full chromatin compaction
[60]. Whereas the C-terminal region of MeCP2 is dispensable for
the two first steps, it is apparently required for maximal compaction
of the chromatin since the R294X mutation abolishes bridging
between nucleosomes [60,61]. By contrast, the R133C mutation,
which abolishes the selective recognition of methylated DNA, retains
the chromatin compaction properties of the wild-type protein [30].
The two other point mutations we tested in this study, T158M and
R306C, like R133C, may retain their compaction properties and
thus their repressive effect on MHC genes. Our findings with the
truncated form R308*, which also retains the same repressive effect
on MHC class I expression as the wild-type protein, indicate that the
repression of MHC genes by MeCP2 does not involve the C-
terminal portion of the protein. The effects of MeCP2 on MHC
expression therefore probably does not involve the third step of
MeCP2-induced chromatin condensation (above) but may involve a
conformational change in the ‘stem organization’ of the chromatin
around the MHC region [60,61].
If MeCP2 represses MHC class I expression, we expected to see
elevated levels of MHC class I in the brains of MECP2 knockout
mice (strain MeCP2
tm1.1Bird) when compared to mice with fully
functional MECP2 [11]. When we stained brain slices immuno-
histochemically with two different antibodies, we saw a small but
reproducible increase in MHC class I expression in the brains of
three knockout male mice when compared to those of their wild-
type littermates, but these results were purely qualitative, and it
was not possible to quantify these differences by immunohisto-
chemistry. We decided, therefore, to produce primary cultures of
MGCs from knockout mice in order to quantify MHC class I
expression by flow cytometry. This approach also allowed us to
distinguish a neuronal population, comprised of small cells
expressing bIII-tubulin, and a population of large cells comprised
mostly of astrocytes. This quantitative analysis detected no
difference between MHC class I levels on the surface of cells
derived from animals carrying an inactivated MECP2 gene and
those from their wild-type littermates whether for the basal level of
MHC class I expression or for the level induced by IFN-c. This
was true for the neuronal population and the astrocyte population,
as well as for primary cultures of spleen fibroblasts.
We conclude from these studies that there may be a small
quantitative increase in MHC class I in the brains of MECP2
knockout mice when compared to the wild type but this increase is
not seen in isolated primary MGCs containing mostly neurons and
astrocytes. The possibility remains that the levels of MeCP2 in
these primary cell cultures were insufficient to see a difference.
Indeed, our experiments with N2A cells showed that relatively
high levels of MeCP2 are necessary to observe its repressive effect
on MHC class I expression. Several studies have shown a direct
correlation between age and MeCP2 expression, with maximal
levels of expression in post-mitotic mature and differentiated
neurons [52,53,55–57,62]. Although the neuronal populations in
our MGCs expressed bIII-tubulin, a marker of neuronal
differentiation, they were very probably far from being fully
mature. In support of this, we were unable to detect MeCP2
expression in neonatal MGCs by flow cytometry (not shown). The
neurons that we analysed in neonate MGC might therefore have
been too immature to demonstrate a defect in MHC regulation
due to MeCP2 deficiency. It was, however, not feasible to obtain
brain tissue from adult MECP2 knockout animals for these studies
because the mice die at around eight weeks old.
Three groups have performed transcriptome analyses on
microarrays of cDNA prepared from post-mortem brain tissue of
girls with RTT and from the brains of MECP2 knockout mice [63–
65]. At least one of these studies supports the idea that MeCP2
may influence MHC expression in the CNS: Colantuoni et al. [63]
found a 5.8-fold increase in expression of the mRNA for the MHC
class I molecule HLA-A in a RTT syndrome patient relative to
matched controls. This small increase in MHC class I expression
in the absence of MeCP2 is consistent with our hypothesis and
further suggests that such subtle disregulation might be detectable
only in older mice than those we used in our study.
We found that the forms of MeCP2 carrying RTT-causing
mutations retained their repressive function on MHC expression
in transiently transfected cells. Although this observation does not
go against our findings that MeCP2 can down-regulate MHC
expression in cells where it is expressed at high levels, these results
lead us to conclude that repression of MHC class I expression by
MeCP2 is very probably not directly relevant to the pathogenesis
of RTT. Mutations in the MECP2 gene are also suspected to be at
the origin of a large panel of other neurological diseases such as
autism [66,67], Angelman syndrome [68], X-linked mental
retardation [69,70], and severe neonatal encephalopathy
[71,72]. It may therefore be that those types of mutations
responsible for other diseases could be related to the MHC-
regulating activity of MeCP2. Additionally, the majority of
MECP2 mutations in RTT are loss-of-function mutations, but
overexpression of MECP2 by gene duplication in a mouse model
[73], as well as in human clinical cases [74–77], also causes mental
retardation and progressive neurological diseases. Since high levels
of MeCP2 can repress cell surface expression of MHC class I, at
least in neuronal cell lines, MeCP2 overexpression might result in
an overrepression of MHC gene expression in the CNS, which
may contribute to certain pathologies by preventing MHC
molecules from fulfilling their roles during CNS development
and in synaptic plasticity [51]. Inappropriate temporal and spatial
repression of MHC genes by overexpressed MeCP2 might induce
defects in neuronal functions similar to those observed in b2m/
TAP1 deficient mice [41]. Further experiments will be required to
explore this eventuality.
This leaves us with the important conclusion that high levels of
MeCP2, like those found in mature neurons, repress expression of
MHC class I molecules and this may be an important physiological
factor contributing to the repression of MHC class I in the CNS.
MATERIALS AND METHODS
Mice
The MEPC2 knockout mice (MeCP2
tm1.1Bird) were obtained from
the Institute for Stem Cell Research, Edinburgh, UK. These mice have
a RTT-like progressive neurodevelopmental disease very similar to
that seen in patients; the males (2/y) suffer from a much more
severe form of the disease than the heterozygous (+/2) females,
and are sterile. MeCP2
+/2 female mice were mated with C57BL/
6 male mice purchased from the Centre de Recherche et
d’E ´levage, Janvier, France. The litters obtained were genotyped
initially as recommended by the Jackson Laboratory, and later
with an optimised set of primers [78]. All experiments involving
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Cell lines
The N2A and NIH 3T3 cell lines were maintained in DMEM with
10% foetal calf serum (FCS) and antibiotics. For the origin and
description of these cell lines see ATCC.
Antibodies
Polyclonal primary antibodies: rabbit anti-MeCP2 polyclonal IgG
(Upstate), mouse anti- C terminal peptide of MeCP2 (Sigma) and
rabbit anti-beta III-tubulin polyclonal IgG (Abcam).
Hybridoma supernatants from clones (obtained from ATCC):
9E10 (mouse anti-myc IgG1), M1/42 (rat anti-H2 IgG2a), R1-21.2
(rat anti-mouse H2IgG2b),HB25(mouseanti-H2K
k IgG2a),28.14.8
(mouse anti-H2 D
b,L
d and D
q IgG2a), 30.5.7(mouse anti-H2 L
d,D
q
and L
q IgG2a), 34.4.20 (mouse anti-H2 D
d IgG2a), Y-3 (mouse anti-
H2 K
b IgG2b), S19.8 (mouse anti-beta 2 microglobulin b and c
IgG2b), R17.217 (rat anti-mouse transferrin receptor IgG2a).
Secondary fluorescent antibodies: FITC goat anti-mouse IgG
(Dako), fluorescein goat anti-rabbit IgG (H+L) (Molecular Probes,
Invitrogen), AlexaFluor 647 goat anti-rat IgG (H+L) (Molecular
Probes, Invitrogen), AlexaFluor 647 and 680 goat anti-mouse IgG
(H+L) (Molecular Probes, Invitrogen).
Plasmids
pCMX vectors expressing mouse MeCP2a, MeCP2b and human
MeCP2A were described previously [18,79]. pcDNA3.1(A) vectors
expressing Myc-tagged human MeCP2A and MeCP2B [19] were
provided by Dr. Berge A. Minassian of the Hospital for Sick
Children, Toronto, Ontario, Canada.
Mutagenesis
Site-directed mutagenesis of pcDNA3.1(A) vectors driving expres-
sion of Myc-tagged human MeCP2A and MeCP2B was carried out
as described previously [80]. Briefly, during a first PCR reaction
typically [96(95uC for 30 s, 55uCf o r1m i n ,6 8 uC for 1 min)] using
high-fidelity Taq polymerase (Invitrogen), a DNA template was
generated between a forward T7 oligonucleotide (59-GTAATAC-
GACTCACTATAG-39) annealing to pcDNA3.1 (A) upstream of
the multiple cloning site and a reverse oligonucleotide annealing to
the MeCP2 sequence and carrying the chosen mutations:
R133C: 59-aatcaactccactttactgcagaaggcttttccctg-39
T158M: 59-ccctctcccagttaccatgaagtcaaaatcatt-39
R306C: 59-gatgctgaccgtctcacgcgtcttgcacttcttgatggggag-39
These primers were designed to produce or remove a restriction
enzyme site allowing simple screening of the recovered plasmids
(gain of an PstI site for R133C; gain of an NlaIII site for T158M,
and loss of an SmaI site for R306C). During a second PCR
reaction [96(95uC for 30 s, 68uC for 6 min)], the newly amplified
DNA fragments served as megaprimers to complete the synthesis
of the remainder of the plasmids. The extension time of the last
cycle was 16 min, followed by digestion with 10 U DpnIa t3 7 uC
for 1 hr to destroy the original methylated plasmids. The mutated
plasmids were recovered by transforming competent DH5a
bacteria and they were screened by restriction digest. The
sequence of the inserts corresponding to the MeCP2 open reading
frame was then checked by direct sequencing.
To generate pcDNA3.1 plasmids expressing the R308*
truncated forms of Myc-tagged MeCP2A and MeCP2B, a PCR
reaction [126 (94uC, 45 s; 50uC, 45 s; 68uC, 2 min 30 s), 126
(94uC, 45 s; 68uC, 2 min 30 s)] using high-fidelity Taq polymerase
(Invitrogen), was carried out on pcDNA3.1-MeCP2A using the
following oligonucleotides:
Forward T7 primer: 59-GTAATACGACTCACTATAG-39
Reverse primer: 59-gcgtctagagagggtggacaccagca-39
The reverse common primer, annealing in the MECP2 sequence,
was designed to include an XbaI restriction site immediately
following residue 308 of MeCP2, which is also located upstream of
the sequence encoding the Myc tag in the original pcDNA3.1 Myc
plasmid. The amplified MeCP2(1–308) sequence was digested
with XcmI and XbaI and ligated, using T4 DNA ligase (NEB),
into pcDNA3.1 human MeCP2A or B myc-tagged plasmids
digested with the same enzymes. The plasmids expressing
truncated Myc-tagged MeCP2A and B forms were recovered by
transforming competent DH5a bacteria and they were screened
by restriction digest. The sequence of the inserts corresponding to
the MeCP2(R308*) open reading frame was then checked by
direct sequencing.
Transfection
Transfections were carried out using FuGENE 6 (Roche Applied
Bioscience), following the manufacturer’s instructions (using 2 mgo f
plasmid and 6 ml of transfection reagent). Briefly, N2A or NIH 3T3
cells were plated in 25 cm
2 flasks at least 12 hrs before transfection.
Stable N2A transfectants expressing Myc-tagged wild-type and
mutated MeCP2AandMeCP2Bwereselectedbyadding0.5 mg/ml
of G418 three days after transfection, and the populations obtained
were subsequently maintained in this selecting medium.
Quantitative Western Blot
Whole cellular extracts from adult mouse brain, and from
transiently and stably transfected N2A cells were prepared, and
blotted on nitrocellulose after separation by 4–12% SDS-PAGE
(50 mg of cellular extract per sample). Levels of MeCP2 were then
measured on an Odyssey infrared scanner (Li-Cor) after staining
with a mouse anti-MeCP2 polyclonal antibody (C terminal
portion, Sigma), followed by an Alexa 680 anti-mouse secondary
antibody. Normalisation between samples was carried out using a
mouse monoclonal against GAPDH (ab9484, abcam) and the
same secondary reagent on the lower part of the same blot.
Cells staining and cytometry
For immunochemical staining of the cell surface for MHC class I,
b-2-microglobulin or transferrin receptor, cells were harvested by
trypsinisation and washed once with medium to obtain a single-
cell suspension. The resuspended cells were then incubated on ice
with a saturating concentration of the appropriate hybridoma
supernatant. Thirty minutes later, cells were washed three times in
phosphate-buffered saline (PBS) containing 2% FCS, then
incubated for thirty minutes on ice with the suitable secondary
reagent and washed three times before fixation in PBS containing
1% paraformaldehyde. When intracellular MeCP2 or b-III-
tubulin was also analysed, further staining steps were performed
as described above, but adding 0.3% saponin in all buffers.
Labelled cells were analysed using a FACScalibur cytometer and
CellQuest software (BD Biosciences). Dead cells were excluded
using appropriate forward/side scatter gates.
Immunohistochemistry of brain slices
Brains from adult MeCP2
2/y and wild-type mice were embedded
in Tissue-Tek OCT compound (Sakura) and frozen in dry ice-cold
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cryostat at 220uC, placed on Super Frost Plus slides (Menzel-
Gla ¨ser), air dried overnight at room temperature and fixed in
acetone and air dried rapidly. The tissue sections were then
rehydrated in PBS containing 3% bovine serum albumin (BSA)
and endogenous peroxidase activity was quenched by incubating
with peroxydase block reagent (Dako). Following washes in PBS
containing 1% BSA, the specimens were incubated with saturating
concentrations of rat hybridoma supernatant for 1 hr and then
rinsed in PBS containing 1% BSA before incubation with the
rabbit anti-rat Ig antibody Z0494 (Dako). The sections were then
treated with EnVision as instructed by the manufacturer (Dako)
using a labelled polymer-HRP goat anti-rabbit Ig. Finally, slides
were mounted in Mowiol. Observation and image acquisitions
were carried out on a Leica RM-IRB microscope using the 106
objective. Pictures were taken with a COHU CCD camera.
Immunofluorescence staining
N2A cells growing on coverslips were transfected with empty
pcDNA3.1(+), with pcDNA3.1 expressing Myc-tagged wild-type
MeCP2A or B, or pcDNA3.1 expressing Myc-tagged mutated
MeCP2A or B containing the T158M, R133C, R306C or R308*
mutations. Cells were fixed with acetone and incubated with
mouse anti-Myc monoclonal antibody (9E10) followed by FITC-
labelled anti-mouse IgG antibody for 30 min at room tempera-
ture. After the final wash, the coverslips were mounted in DAPI-
containing ProLong Gold antifading reagent (Molecular Probes).
Observation and image acquisition were carried out on a Leica
RM-IRB microscope using 406or 206objectives. Pictures were
taken with a COHU CCD camera and acquired as TIFF stacks of
images with Q-Fluoro software, after integration of the signal for
1 sec for in the case of FITC labelling (no integration of the signal
was necessary for DAPI labelling).
Primary cultures
Brains removed from two-day old mice were cut in small pieces in
ice-cold PBS containing glucose, then centrifuged at 80 g for
5 min at 4uC and digested with trypsin (Gibco) for 40 min at
37uC. The trypsin was blocked by adding DMEM supplemented
with 10% FCS for 5 min at room temperature. The digested brain
material was then washed twice with DMEM containing 10%
FCS and once in neurobasal medium (Gibco) supplemented with
B27 and 2% FCS, and recovered between washes by centrifuga-
tion at 80 g for 5 min at 4uC. During the final wash, mechanical
dissociation of the cells into a single-cell suspension was achieved
by pipetting up and down several times. Brain cell suspensions
were plated on six-well plates coated at least 12 hrs before with
poly-D-ornithine (SIGMA) and maintained in neurobasal medium
containing B27 and 2% FCS.
For cultures of splenic fibroblasts, spleens were cut into small
pieces in PBS/glucose, digested in trypsin and washed, as above,
and finally plated on six-well plates and maintained in RPMI
containing 10% FCS.
ACKNOWLEDGMENTS
We would like to thank Dr. Brian Hendrich for his gift of reagents and
helpful discussions, Drs Berge Minassian, and Adrian Bird for their gifts of
plasmids, Denis Hudrisier and Jean Charles Gue ´ry for helpful suggestions
and discussions, and Carol Featherstone for her help with the manuscript.
Author Contributions
Conceived and designed the experiments: EJ JM. Performed the
experiments: EM JM LK SP HB. Analyzed the data: EJ JM LK SP.
Wrote the paper: EJ JM.
REFERENCES
1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, et al. (1999) Rett
syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-
binding protein 2. Nat Genet 23: 185–188.
2. Sirianni N, Naidu S, Pereira J, Pillotto RF, Hoffman EP (1998) Rett syndrome:
confirmation of X-linked dominant inheritance, and localization of the gene to
Xq28. Am J Hum Genet 63: 1552–1558.
3. Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P, et al. (2000) MECP2
mutations account for most cases of typical forms of Rett syndrome. Hum Mol
Genet 9: 1377–1384.
4. Percy AK (2002) Rett syndrome. Current status and new vistas. Neurol Clin 20:
1125–1141.
5. Hagberg B, Aicardi J, Dias K, Ramos O (1983) A progressive syndrome of
autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s
syndrome: report of 35 cases. Ann Neurol 14: 471–479.
6. Neul JL, Zoghbi HY (2004) Rett syndrome: a prototypical neurodevelopmental
disorder. Neuroscientist 10: 118–128.
7. Zoghbi HY (2005) MeCP2 dysfunction in humans and mice. J Child Neurol 20:
736–740.
8. Quaderi NA, Meehan RR, Tate PH, Cross SH, Bird AP, et al. (1994) Genetic
and physical mapping of a gene encoding a methyl CpG binding protein,
Mecp2, to the mouse X chromosome. Genomics 22: 648–651.
9. D’Esposito M, Quaderi NA, Ciccodicola A, Bruni P, Esposito T, et al. (1996)
Isolation, physical mapping, and northern analysis of the X-linked human gene
encoding methyl CpG-binding protein, MECP2. Mamm Genome 7: 533–535.
10. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG
binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat
Genet 27: 327–331.
11. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null
mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet
27: 322–326.
12. Pelka GJ, Watson CM, Radziewic T, Hayward M, Lahooti H, et al. (2006)
Mecp2 deficiency is associated with learning and cognitive deficits and altered
gene activity in the hippocampal region of mice. Brain 129: 887–898.
13. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, et al. (2002)
Mice with truncated MeCP2 recapitulate many Rett syndrome features and
display hyperacetylation of histone H3. Neuron 35: 243–254.
14. Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, et al. (2006) Postnatal
loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate
behavioral aspects of Rett syndrome in mice. Biol Psychiatry 59: 468–476.
15. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R (2004) Expression of MeCP2
in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci U S A
101: 6033–6038.
16. Giacometti E, Luikenhuis S, Beard C, Jaenisch R (2007) Partial rescue of
MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A
104: 1931–1936.
17. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects
in a mouse model of Rett syndrome. Science 315: 1143–1147.
18. Kriaucionis S, Bird A (2004) The major form of MeCP2 has a novel N-terminus
generated by alternative splicing. Nucleic Acids Res 32: 1818–1823.
19. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, et al. (2004) A
previously unidentified MECP2 open reading frame defines a new protein
isoform relevant to Rett syndrome. Nat Genet 36: 339–341.
20. Nan X, Campoy FJ, Bird A (1997) MeCP2 is a transcriptional repressor with
abundant binding sites in genomic chromatin. Cell 88: 471–481.
21. Nan X, Meehan RR, Bird A (1993) Dissection of the methyl-CpG binding
domain from the chromosomal protein MeCP2. Nucleic Acids Res 21:
4886–4892.
22. Nan X, Tate P, Li E, Bird A (1996) DNA methylation specifies chromosomal
localization of MeCP2. Mol Cell Biol 16: 414–421.
23. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, et al.
(2005) DNA binding selectivity of MeCP2 due to a requirement for A/T
sequences adjacent to methyl-CpG. Mol Cell 19: 667–678.
24. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. (1998)
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves
a histone deacetylase complex. Nature 393: 386–389.
25. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, et al. (1998)
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcrip-
tion. Nat Genet 19: 187–191.
26. Kaludov NK, Wolffe AP (2000) MeCP2 driven transcriptional repression in
vitro: selectivity for methylated DNA, action at a distance and contacts with the
basal transcription machinery. Nucleic Acids Res 28: 1921–1928.
MeCP2 Reduces MHC I Expression
PLoS ONE | www.plosone.org 10 December 2007 | Issue 12 | e135427. Kokura K, Kaul SC, Wadhwa R, Nomura T, Khan MM, et al. (2001) The Ski
protein family is required for MeCP2-mediated transcriptional repression. J Biol
Chem 276: 34115–34121.
28. Jeffery L, Nakielny S (2004) Components of the DNA methylation system of
chromatin control are RNA-binding proteins. J Biol Chem 279: 49479–49487.
29. Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, et al. (2005)
Regulation of RNA splicing by the methylation-dependent transcriptional
repressor methyl-CpG binding protein 2. Proc Natl Acad Sci U S A 102:
17551–17558.
30. Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, et al.
(2003) Chromatin compaction by human MeCP2. Assembly of novel secondary
chromatin structures in the absence of DNA methylation. J Biol Chem 278:
32181–32188.
31. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T (2005) Loss of
silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome.
Nat Genet 37: 31–40.
32. Kimura H, Shiota K (2003) Methyl-CpG-binding protein, MeCP2, is a target
molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 278:
4806–4812.
33. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, et al. (2003) The methyl-CpG-
binding protein MeCP2 links DNA methylation to histone methylation. J Biol
Chem 278: 4035–4040.
34. Chen WG, Chang Q, Lin Y, Meissner A, West AE, et al. (2003) Derepression of
BDNF transcription involves calcium-dependent phosphorylation of MeCP2.
Science 302: 885–889.
35. Martinowich K, Hattori D, Wu H, Fouse S, He F, et al. (2003) DNA
methylation-related chromatin remodeling in activity-dependent BDNF gene
regulation. Science 302: 890–893.
36. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R (2006) The disease
progression of Mecp2 mutant mice is affected by the level of BDNF expression.
Neuron 49: 341–348.
37. Peddada S, Yasui DH, LaSalle JM (2006) Inhibitors of differentiation (ID1, ID2,
ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett
syndrome. Hum Mol Genet 15: 2003–2014.
38. Nuber UA, Kriaucionis S, Roloff TC, Guy J, Selfridge J, et al. (2005) Up-
regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome.
Hum Mol Genet 14: 2247–2256.
39. Tykocinski ML, Max EE (1984) CG dinucleotide clusters in MHC genes and in
59 demethylated genes. Nucleic Acids Res 12: 4385–4396.
40. Corriveau RA, Huh GS, Shatz CJ (1998) Regulation of class I MHC gene
expression in the developing and mature CNS by neural activity. Neuron 21:
505–520.
41. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, et al. (2000)
Functional requirement for class I MHC in CNS development and plasticity.
Science 290: 2155–2159.
42. Neumann H, Cavalie A, Jenne DE, Wekerle H (1995) Induction of MHC class I
genes in neurons. Science 269: 549–552.
43. Syken J, Shatz CJ (2003) Expression of T cell receptor beta locus in central
nervous system neurons. Proc Natl Acad Sci U S A 100: 13048–13053.
44. Ishii T, Hirota J, Mombaerts P (2003) Combinatorial coexpression of neural and
immune multigene families in mouse vomeronasal sensory neurons. Curr Biol
13: 394–400.
45. Loconto J, Papes F, Chang E, Stowers L, Jones EP, et al. (2003) Functional
expression of murine V2R pheromone receptors involves selective association
with the M10 and M1 families of MHC class Ib molecules. Cell 112: 607–618.
46. Leinders-Zufall T, Brennan P, Widmayer P, S PC, Maul-Pavicic A, et al. (2004)
MHC class I peptides as chemosensory signals in the vomeronasal organ.
Science 306: 1033–1037.
47. Gobin SJ, van Zutphen M, Woltman AM, van den Elsen PJ (1999)
Transactivation of classical and nonclassical HLA class I genes through the
IFN-stimulated response element. J Immunol 163: 1428–1434.
48. Shahbazian MD, Zoghbi HY (2001) Molecular genetics of Rett syndrome and
clinical spectrum of MECP2 mutations. Curr Opin Neurol 14: 171–176.
49. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, et al. (1992)
Purification, sequence, and cellular localization of a novel chromosomal protein
that binds to methylated DNA. Cell 69: 905–914.
50. McLaren FH, Svendsen CN, Van der Meide P, Joly E (2001) Analysis of neural
stem cells by flow cytometry: cellular differentiation modifies patterns of MHC
expression. J Neuroimmunol 112: 35–46.
51. Goddard CA, Butts DA, Shatz CJ (2007) Regulation of CNS synapses by
neuronal MHC class I. Proc Natl Acad Sci U S A.
52. Jung BP, Jugloff DG, Zhang G, Logan R, Brown S, et al. (2003) The expression
of methyl CpG binding factor MeCP2 correlates with cellular differentiation in
the developing rat brain and in cultured cells. J Neurobiol 55: 86–96.
53. Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon OH, et al. (2003) Expression
of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs
before synaptogenesis. Mol Cell Neurosci 22: 417–429.
54. Mullaney BC, Johnston MV, Blue ME (2004) Developmental expression of
methyl-CpG binding protein 2 is dynamically regulated in the rodent brain.
Neuroscience 123: 939–949.
55. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY (2002) Insight into Rett
syndrome: MeCP2 levels display tissue- and cell-specific differences and
correlate with neuronal maturation. Hum Mol Genet 11: 115–124.
56. Kishi N, Macklis JD (2004) MECP2 is progressively expressed in post-migratory
neurons and is involved in neuronal maturation rather than cell fate decisions.
Mol Cell Neurosci 27: 306–321.
57. LaSalle JM, Goldstine J, Balmer D, Greco CM (2001) Quantitative localization
of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression pheno-
types in normal and Rett syndrome brain by laser scanning cytometry. Hum
Mol Genet 10: 1729–1740.
58. Ritz U, Seliger B (2001) The transporter associated with antigen processing
(TAP): structural integrity, expression, function, and its clinical relevance. Mol
Med 7: 149–158.
59. York IA, Rock KL (1996) Antigen processing and presentation by the class I
major histocompatibility complex. Annu Rev Immunol 14: 369–396.
60. Nikitina T, Shi X, Ghosh RP, Horowitz-Scherer RA, Hansen JC, et al. (2007)
Multiple modes of interaction between the methylated DNA binding protein
MeCP2 and chromatin. Mol Cell Biol 27: 864–877.
61. Nikitina T, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Grigoryev SA, et al.
(2007) MeCP2-chromatin interactions include the formation of chromatosome-
like structures and are altered in mutations causing Rett syndrome. J Biol
Chem..
62. Balmer D, Goldstine J, Rao YM, LaSalle JM (2003) Elevated methyl-CpG-
binding protein 2 expression is acquired during postnatal human brain
development and is correlated with alternative polyadenylation. J Mol Med
81: 61–68.
63. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, et al. (2001)
Gene expression profiling in postmortem Rett Syndrome brain: differential gene
expression and patient classification. Neurobiol Dis 8: 847–865.
64. Tudor M, Akbarian S, Chen RZ, Jaenisch R (2002) Transcriptional profiling of
a mouse model for Rett syndrome reveals subtle transcriptional changes in the
brain. Proc Natl Acad Sci U S A 99: 15536–15541.
65. Traynor J, Agarwal P, Lazzeroni L, Francke U (2002) Gene expression patterns
vary in clonal cell cultures from Rett syndrome females with eight different
MECP2 mutations. BMC Med Genet 3: 12.
66. Lam CW, Yeung WL, Ko CH, Poon PM, Tong SF, et al. (2000) Spectrum of
mutations in the MECP2 gene in patients with infantile autism and Rett
syndrome. J Med Genet 37: E41.
67. Beyer KS, Blasi F, Bacchelli E, Klauck SM, Maestrini E, et al. (2002) Mutation
analysis of the coding sequence of the MECP2 gene in infantile autism. Hum
Genet 111: 305–309.
68. Watson P, Black G, Ramsden S, Barrow M, Super M, et al. (2001) Angelman
syndrome phenotype associated with mutations in MECP2, a gene encoding a
methyl CpG binding protein. J Med Genet 38: 224–228.
69. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, et al. (2001)
MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 10:
941–946.
70. Orrico A, Lam C, Galli L, Dotti MT, Hayek G, et al. (2000) MECP2 mutation
in male patients with non-specific X-linked mental retardation. FEBS Lett 481:
285–288.
71. Clayton-Smith J, Watson P, Ramsden S, Black GC (2000) Somatic mutation in
MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 356:
830–832.
72. Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, et al. (2000) Two
affected boys in a Rett syndrome family: clinical and molecular findings.
Neurology 55: 1188–1193.
73. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, et al.
(2004) Mild overexpression of MeCP2 causes a progressive neurological disorder
in mice. Hum Mol Genet 13: 2679–2689.
74. Ariani F, Mari F, Pescucci C, Longo I, Bruttini M, et al. (2004) Real-time
quantitative PCR as a routine method for screening large rearrangements in
Rett syndrome: Report of one case of MECP2 deletion and one case of MECP2
duplication. Hum Mutat 24: 172–177.
75. Meins M, Lehmann J, Gerresheim F, Herchenbach J, Hagedorn M, et al. (2005)
Submicroscopic duplication in Xq28 causes increased expression of the MECP2
gene in a boy with severe mental retardation and features of Rett syndrome.
J Med Genet 42: e12.
76. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, et al. (2005)
Duplication of the MECP2 region is a frequent cause of severe mental
retardation and progressive neurological symptoms in males. Am J Hum Genet
77: 442–453.
77. Lugtenberg D, de Brouwer AP, Kleefstra T, Oudakker AR, Frints SG, et al.
(2006) Chromosomal copy number changes in patients with non-syndromic X
linked mental retardation detected by array CGH. J Med Genet 43: 362–370.
78. Miralves J, Magdeleine E, Joly E (2007) Design of an improved set of
oligonucleotide primers for genotyping MeCP2tm1.1Bird KO mice by PCR.
Mol Neurodegener 2: 16.
79. Hendrich B, Bird A (1998) Identification and characterization of a family of
mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538–6547.
80. Kirsch RD, Joly E (1998) An improved PCR-mutagenesis strategy for two-site
mutagenesis or sequence swapping between related genes. Nucleic Acids Res 26:
1848–1850.
MeCP2 Reduces MHC I Expression
PLoS ONE | www.plosone.org 11 December 2007 | Issue 12 | e1354